Miesbach Wolfgang
Medical Clinic III, Institute of Transfusion Medicine, University Hospital, Johann Wolfgang Goethe-University, Frankfurt, Germany.
Clin Rev Allergy Immunol. 2009 Jun;36(2-3):91-7. doi: 10.1007/s12016-008-8101-2.
The catastrophic anti-phospholipid (Asherson's) syndrome (CAPS) is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels and differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. Malignancy may play a pathogenic role in patients with CAPS, whereas infections are more important as triggering factors in patients without malignancies. CAPS patients with malignancies are generally older than CAPS patients without malignancies; they generally have the worst prognosis of the entire CAPS cohort.
灾难性抗磷脂（阿舍森氏）综合征（CAPS）的特征是暴发性血栓形成并发症迅速按时间顺序发展，主要影响小血管，并且在其加速的全身受累导致多器官功能衰竭方面与抗磷脂综合征不同。恶性肿瘤可能在CAPS患者中起致病作用，而感染在无恶性肿瘤的患者中作为触发因素更为重要。患有恶性肿瘤的CAPS患者通常比没有恶性肿瘤的CAPS患者年龄更大；他们通常在整个CAPS队列中预后最差。
